Druggio Logo

Druggio

HIV infection

The human immunodeficiency virus (HIV) is a lentivirus (a subgroup of retrovirus) that causes HIV infection and over time acquired immunodeficiency syndrome (AIDS). Two types of HIV has been characterized. HIV-1 is the most virulent and pathogenic strain. Worldwide, the predominant virus is HIV-1. The relatively uncommon HIV-2 type is concentrated in West Africa and is rarely found elsewhere. Infection with HIV occurs by transfer of blood, semen, and breast milk. The identification of HIV as the causative agent of AIDS catalyzed efforts to develop antiviral agents. The licenced anti-HIV drugs fall into some categories: reverse transcriptase inhibitors (NRTIs and NNRTIs), integrase inhibitors, protease inhibitors (PIs), fusion inhibitors (FIs), and coreceptor inhibitors. The advent of highly active antiretroviral therapy (HAART) as the standard of care for the treatment of HIV infection was seminal in reducing the morbidity and mortality associated with HIV infection and progression to AIDS. Combination antiretroviral therapy dramatically suppresses HIV replication and reduces the plasma HIV-1 viral load, resulting in significant reconstitution of the immune system.

Drugs that treat HIV infection

Pifeltro

Made by

MSD

Approval date

2020/1/14

Biktarvy

Approval date

2019/3/26

Genvoya

Approval date

2016/6/17

Tivicay

Approval date

2014/3/24

Stribild

Approval date

2013/3/25

Edurant

Approval date

2012/5/18

Celsentri

Made by

Pfizer

Approval date

2008/12/25

Intelence

Approval date

2008/12/25

Isentress

Made by

MSD

Approval date

2008/6/24

Prezista

Approval date

2007/11/22

Emtriva

Approval date

2005/3/23

Truvada

Approval date

2005/3/23

Lexiva

Approval date

2004/12/24

Reyataz

Approval date

2003/12/18

Kaletra

Approval date

2000/12/12